Programmed death-1 (PD-1) is an inhibitory receptor expressed on a variety of immune cells, including activated T cells, regulatory T cells, and B cells. Interaction between PD-1 and its ligands, PD-L1 or PD-L2, leads to downregulation of effector T cell responses and mediates immune tolerance. PD-1 and PD-L1 are commonly upregulated on tumor-infiltrating lymphocytes and a wide variety of tumor cells, respectively. Monoclonal antibodies (mAbs) targeting PD-1 can restore effector T cell function and antitumor activity and have shown clinical benefit in patients with advanced cancers. LVGN3616 is a humanized IgG4κ mAb that binds PD-1 with high affinity in vitro and blocks interaction with PD-L1/PD-L2 in cell-based assays. LVGN3616 has also demonstrated pharmacodynamic (PD) activity and a favorable toxicology profile in preclinical studies. The ongoing first-in-human phase I study is designed to investigate the safety, pharmacokinetics (PK), and efficacy of LVGN3616 in patients with advanced or metastatic tumors.
We are conducting Phase I trials of LVGN3616 in China and the USA.
If you as a patient or caregiver wish to participate in this study, please contact us at the following address: firstname.lastname@example.org or send us a message.